Using Poly I:C as an adjuvant does not induce or exacerbate models of systemic lupus erythematosus

References

• Pashine, A., N. M. Valiante, and J. B. Ulmer. 2005. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 11: S63–S68
   Google Scholar
• Ahmed, S. S., S. A. Plotkin, S. Black, and R. L. Coffman. 2011. Assessing the safety of adjuvanted vaccines. Sci. Transl. Med. 3: 93rv92
   Web of Science ®Google Scholar
• Duthie, M. S., H. P. Windish, C. B. Fox, and S. G. Reed. 2011. Use of defined TLR ligands as adjuvants within human vaccines. Immunol. Rev. 239: 178–196
   PubMed Web of Science ®Google Scholar
• Pulendran, B., and R. Ahmed. 2011. Immunological mechanisms of vaccination. Nat. Immunol. 131: 509–517
   Google Scholar
• Mbow, M. L., E. De Gregorio, N. M. Valiante, and R. Rappuoli. 2010. New adjuvants for human vaccines. Curr. Opin. Immunol. 22: 411–416
   PubMed Web of Science ®Google Scholar
• Coffman, R. L., A. Sher, and R. A. Seder. 2010. Vaccine adjuvants: putting innate immunity to work. Immunity 33: 492–503
   PubMed Web of Science ®Google Scholar
• Fox, C. B., M. Friede, S. G. Reed, and G. C. Ireton. 2010. Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants. Subcell. Biochem. 53: 303–321
   PubMedGoogle Scholar
• Novak, N., C. F. Yu, T. Bieber, and J. P. Allam. 2008. Toll-like receptor 7 agonists and skin. Drug News. Perspect. 21: 158–165
   PubMedGoogle Scholar
• Poltorak, A., X. He, I. Smirnova, et al. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282: 2085–2088
   PubMed Web of Science ®Google Scholar
• Pisitkun, P., J. A. Deane, M. J. Difilippantonio, et al. 2006. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312: 1669–1672
   PubMed Web of Science ®Google Scholar
• Deane, J. A., P. Pisitkun, R. S. Barrett, et al. 2007. Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity 27: 801–810
   PubMed Web of Science ®Google Scholar
• Marshak-Rothstein, A., and I. R. Rifkin. 2007. Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. Annu. Rev. Immunol. 25: 419–441
   PubMed Web of Science ®Google Scholar
• Leadbetter, E. A., I. R. Rifkin, A. M. Hohlbaum, et al. 2002. Chromatin-IgG complexes activate B cells by dual engagement of IgM and toll-like receptors. Nature 416: 603–607
   PubMed Web of Science ®Google Scholar
• Christensen, S. R., and M. J. Shlomchik. 2007. Regulation of lupus-related autoantibody production and clinical disease by toll-like receptors. Semin. Immunol. 19: 11–23
   PubMed Web of Science ®Google Scholar
• Nickerson, K. M., S. R. Christensen, J. Shupe, et al. 2010. TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus. J. Immunol. 184: 1840–1848
   PubMed Web of Science ®Google Scholar
• Christensen, S. R., J. Shupe, K. Nickerson, et al. 2006. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25: 417–428
   PubMed Web of Science ®Google Scholar
• Teichmann, L. L., D. Schenten, R. Medzhitov, et al. 2013. Signals via the adaptor MyD88 in B cells and DCs make distinct and synergistic contributions to immune activation and tissue damage in lupus. Immunity 38: 528–540
   PubMed Web of Science ®Google Scholar
• Barrat, F. J., T. Meeker, J. H. Chan, et al. 2007. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur. J. Immunol. 37: 3582–3586
   PubMed Web of Science ®Google Scholar
• Yu, D., D. Wang, F. G. Zhu, et al. 2009. Modifications incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of toll-like receptors 7 and 9. J. Med. Chem. 52: 5108–5114
   PubMed Web of Science ®Google Scholar
• Hang, L., J. H. Slack, C. Amundson, et al. 1983. Induction of murine autoimmune disease by chronic polyclonal B cell activation. J. Exp. Med. 157: 874–883
   PubMed Web of Science ®Google Scholar
• Patole, P. S., H. J. Grone, S. Segerer, et al. 2005. Viral double-stranded RNA aggravates lupus nephritis through toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. J. Am. Soc. Nephrol. 16: 1326–1338
   PubMed Web of Science ®Google Scholar
• Patole, P. S., and H. J. Anders. 2006. Nucleic acids modulate autoimmunity through nucleic-acid-specific toll-like receptors. Curr. Med. Chem. 13: 3061–3067
   PubMedGoogle Scholar
• Pawar, R. D., P. S. Patole, D. Zecher, et al. 2006. Toll-like receptor-7 modulates immune complex glomerulonephritis. J. Am. Soc. Nephrol. 17: 141–149
   Google Scholar
• Tewari, K., B. J. Flynn, S. B. Boscardin, et al. 2010. Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and alphaDEC-CSP in non human primates. Vaccine 28: 7256–7266
   PubMed Web of Science ®Google Scholar
• Bolland, S., and J. V. Ravetch. 2000. Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity. 13: 277–285
   PubMed Web of Science ®Google Scholar
• Tarasenko, T., J. A. Dean, and S. Bolland. 2007. FcgammaRIIB as a modulator of autoimmune disease susceptibility. Autoimmunity 40: 409–417
   PubMed Web of Science ®Google Scholar
• Elinav, E., T. Strowig, J. Henao-Mejia, and R. A. Flavell. 2011. Regulation of the antimicrobial response by NLR proteins. Immunity 34: 665–679
   PubMed Web of Science ®Google Scholar
• Kawai, T., and S. Akira. 2011. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 34: 637–650
   PubMed Web of Science ®Google Scholar
• Loo, Y. M., and M. Gale. Jr. 2011. Immune signaling by RIG-I-like receptors. Immunity 34: 680–692
   PubMed Web of Science ®Google Scholar
• Osorio, F., and C. Reis e Sousa. 2011. Myeloid C-type lectin receptors in pathogen recognition and host defense. Immunity 34: 651–664
   PubMed Web of Science ®Google Scholar
• Keam, S. J., and D. M. Harper. 2008. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix]: profile report. BioDrugs 22: 205–208
   PubMed Web of Science ®Google Scholar
• Nickerson, K. M., S. R. Christensen, J. Shupe, et al. 2010. TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus. J. Immunol. 184: 1840–1848
   PubMed Web of Science ®Google Scholar
• Wu, X., and S. L. Peng. 2006. Toll-like receptor 9 signaling protects against murine lupus. Arthritis Rheum. 54: 336–342
   PubMed Web of Science ®Google Scholar
• Maldonado, M. A., V. Kakkanaiah, G. C. MacDonald, et al. 1999. The role of environmental antigens in the spontaneous development of autoimmunity in MRL-lpr mice. J. Immunol. 162: 6322–6330
   PubMed Web of Science ®Google Scholar
• Green, N. M., K. S. Moody, M. Debatis, and A. Marshak-Rothstein. 2012. Activation of autoreactive B cells by endogenous TLR7 and TLR3 RNA ligands. J. Biol. Chem. 287: 39789–39799
   PubMed Web of Science ®Google Scholar
• Touil, T., D. Fitzgerald, G. X. Zhang, et al. 2006. Cutting edge: TLR3 stimulation suppresses experimental autoimmune encephalomyelitis by inducing endogenous IFN-beta. J. Immunol. 177: 7505–7509
   PubMed Web of Science ®Google Scholar